BioLineRx has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Correspondingly, What is BioLineRx? BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs.
Who makes Motixafortide? BioLineRx is a late clinical-stage biopharmaceutical company advancing lead candidate Motixafortide (BL-8040), a platform molecule targeting indications in stem cell mobilization for multiple myeloma (MM) and in the treatment of advanced pancreatic cancer.
Furthermore, Will Blrx stock go up?
BioLine RX Ltd (NASDAQ:BLRX)
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 10.00, with a high estimate of 19.00 and a low estimate of 7.25. The median estimate represents a +506.06% increase from the last price of 1.65.
Is Blrx a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank.
…
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.93% |
| 2 | Buy | 18.44% |
| 3 | Hold | 9.99% |
| 4 | Sell | 5.61% |
Should I buy Blrx stock? BioLineRx Ltd.
finds support from accumulated volume at $1.57 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock has average movements during the day and with good trading volume, the risk is considered to be medium.
Is Blrx a good stock to buy? The consensus among 2 Wall Street analysts covering (NASDAQ: BLRX) stock is to Strong Buy BLRX stock.
